A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.

Eleftheria Kalogera Wendy K Nevala Heidi D Finnes Vera J Suman Jill M Schimke Carrie A Strand Lisa A Kottschade Rachel A Kudgus Sarah A Buhrow Laura R Elsbernd Liyi Geng Gretchen E Glaser Megan E Grudem Aminah Jatoi Carolyn M Klampe Amanika Kumar Carrie L Langstraat Robert R McWilliams Andrea E Wahner Hendrickson John S Weroha Yiyi Yan Joel M Reid Svetomir N Markovic Matthew S Block

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The safety profile and clinical activity of AB160 supports further clinical testing in patients with gynecologic cancers; the RP2D is DL2 (ABX 150 mg/m2, BEV 60 mg/m2).

Keyphrases

randomized controlled trial